Compare the PHQ-9, GAD-7, and PCL-5 mental health assessments. The PHQ-9 measures depression severity (9 items, score 0-27, cutoff ≥10). The GAD-7 measures generalized anxiety (7 items, score 0-21, cutoff ≥10). The PCL-5 measures PTSD symptoms (20 items, score 0-80, cutoff 31-33). Use the PHQ-9 and GAD-7 together in primary care and outpatient settings. Use the PCL-5 for patients with trauma history.
PHQ-9 vs GAD-7 vs PCL-5
When to Use Each
Three of the most widely used validated assessments in mental health, compared side by side. Know which tool to reach for and when.
Side-by-Side Comparison
| Feature | PHQ-9 | GAD-7 | PCL-5 |
|---|---|---|---|
| Measures | Depression severity | Anxiety severity | PTSD symptoms |
| Questions | 9 | 7 | 20 |
| Score Range | 0 – 27 | 0 – 21 | 0 – 80 |
| Clinical Cutoff | ≥ 10 | ≥ 10 | 31–33 |
| Rating Scale | 0 = Not at all, 3 = Nearly every day | 0 = Not at all, 3 = Nearly every day | 0 = Not at all, 4 = Extremely |
| Timeframe | Past 2 weeks | Past 2 weeks | Past month |
| Completion Time | 2–3 min | 2–3 min | 5–10 min |
| DSM-5 Aligned | |||
| Free to use, no permission needed | |||
| Primary Use | Screening + MBC monitoring | Screening + MBC monitoring | Assessment support + trauma monitoring |
| Often Used With | GAD-7, PHQ-2, ASRS | PHQ-9, AUDIT | C-SSRS, LEC-5 |
| HiBoop Assessment | Open | Open | Open |
When to Use Each Assessment
Choosing the right tool for the right patient at the right time is the foundation of effective measurement-based care.
PHQ-9
Use the PHQ-9 when your clinical concern is depression. Ideal for:
- Primary care intake screening
- Routine MBC monitoring for MDD
- Evaluating antidepressant response
- Perinatal / postpartum screening
- Combined with GAD-7 for comorbid screening
Item 9 ≥ 1 = suicidal ideation, immediate safety evaluation required.
GAD-7
Use the GAD-7 when your clinical concern is anxiety. Ideal for:
- Screening for generalized anxiety disorder
- Monitoring anxiety alongside PHQ-9
- Detecting panic disorder and social anxiety
- Integrated primary care workflows
- Population health screening programs
Score ≥ 15 = severe anxiety, active intervention recommended.
PCL-5
Use the PCL-5 when your clinical concern is trauma / PTSD. Ideal for:
- Patients with known trauma history
- Veterans and military populations
- Residential and IOP treatment programs
- Monitoring CPT and PE treatment response
- Combined with C-SSRS for high-risk patients
Reliable change = 5–10 point reduction from baseline.
Using the PHQ-9 and GAD-7 Together
The PHQ-9 and GAD-7 are frequently administered together because depression and anxiety are highly comorbid, up to 60% of patients with major depression also meet criteria for an anxiety disorder. Both tools share the same 4-point rating scale and 2-week timeframe, making paired administration natural.
In measurement-based care workflows, running both tools at intake and every 4 weeks provides a detailed picture of the most common outpatient mental health presentations in under 5 minutes of patient time.
- • Primary care integrated behavioural health
- • Collaborative care models (IMPACT, DIAMOND)
- • Outpatient therapy intake batteries
- • University and college counselling centers
When both PHQ-9 ≥ 10 and GAD-7 ≥ 10, the clinical picture warrants evaluation of both MDD and GAD. A PHQ-9 elevated alone suggests pure depression; GAD-7 elevated alone suggests pure anxiety.
Scoring Interpretation at a Glance
PHQ-9 Score Guide
GAD-7 Score Guide
PCL-5 Score Guide
Clinically significant: 10–20 pts
Clinical Decision Framework
Start with the presenting concern. One question usually narrows the field.
Patient reports persistent sadness, loss of interest, or sleep and appetite changes.
Patient describes uncontrollable worry, tension, or somatic anxiety symptoms.
Patient has known adverse events, re-experiencing symptoms, or is in a trauma-focused program.
In most outpatient intakes, administer PHQ-9 + GAD-7 together. Add PCL-5 when trauma history is flagged.
Measurement-based care
…starts with what we measure, and how long.
Send your first check-in today, with your own assessments and clients. For teams, we set up your assessments and schedules with you.
Start- A guided tour with your own assessments and workflow.Walkthrough
- Everything in HiBoop, by workflow, and what shipped lately.Features
- 100+ validated measures, with scoring guides and sources.Assessments
Frequently Asked Questions
What is the difference between the PHQ-9 and GAD-7?
The PHQ-9 measures depression severity across 9 DSM-5 criteria items, scored 0–27. The GAD-7 measures anxiety severity across 7 items, scored 0–21. Both use the same 0–3 rating scale and 2-week timeframe. They are frequently administered together due to the high comorbidity between depression and anxiety.
Can I use the PHQ-9 and GAD-7 at the same time?
Yes, and it is recommended. Administering both together takes under 5 minutes and captures the two most common mental health presentations. This approach is standard in collaborative care models, integrated primary care, and measurement-based care programs.
What is a concerning GAD-7 score?
A GAD-7 score of 10 or above indicates moderate anxiety and is the standard clinical threshold for treatment consideration. Scores of 15 or higher indicate severe anxiety.
Is the PHQ-9 free to use?
Yes. Pfizer states that no permission is required to reproduce, translate, display or distribute the PHQ-9 and GAD-7, which were developed by Drs. Spitzer, Kroenke, Williams and Löwe with an educational grant from Pfizer. The PCL-5, from the VA National Center for PTSD, is in the public domain.
How accurate are the PHQ-9, GAD-7, and PCL-5?
Each scale has strong psychometric validation. The PHQ-9 at a cutoff of 10 has 88% sensitivity and 88% specificity for major depression (Kroenke et al., 2001). The GAD-7 at a cutoff of 10 has 89% sensitivity and 82% specificity for generalized anxiety disorder (Spitzer et al., 2006). The PCL-5 at a cutoff of 31 to 33 has 76 to 81% sensitivity and 71 to 86% specificity for PTSD (Bovin et al., 2016). All three are validated screeners that support clinical decision-making but are not a substitute for a full clinical evaluation.
How often should the PHQ-9, GAD-7, or PCL-5 be administered?
Best practice for measurement-based care is to administer the primary symptom scale at every session: PHQ-9 weekly for depression treatment, GAD-7 weekly for anxiety treatment, PCL-5 every 2 to 4 weeks for PTSD treatment due to its longer length. Session-by-session cadence is what produces the documented 17 to 40 percent outcome improvement over treatment as usual reported in MBC meta-analyses. Less frequent intervals miss the window where score changes can prompt timely treatment adjustments.
Can the PHQ-9, GAD-7, and PCL-5 be billed under CPT 96127?
Yes. CPT 96127 (Brief emotional/behavioural assessment, with scoring and documentation, per standardized scale) covers each of these three screeners. A single visit can bill up to 4 units of 96127, so a clinician administering PHQ-9, GAD-7, and PCL-5 together with one other scale could bill 4 units. Each unit billed must have the scale name, total score, severity band, and clinical interpretation documented. Reimbursement is typically $4 to $6 per unit and adds up significantly across patient panels.